Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Dendritic cells
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Aug 2024 Status changed from active, no longer recruiting to completed.
- 30 Jul 2024 Planned End Date changed from 31 Oct 2024 to 5 Mar 2025.
- 30 Jul 2024 Planned primary completion date changed from 31 Oct 2024 to 5 Mar 2025.